Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity

Cao Xi, Peilin Liu, Xianshu Gao, Shiyu Shang, Jiayu Liu, Zishen Wang, Mengmeng Su, Xuanfeng DingFrontiers in Oncology 2022 · DOI

TL;DR

This study investigates whether Intensity-Modulated Proton Therapy (IMPT) can reduce acute hematologic toxicity (HT3+) in locally advanced non-small cell lung cancer (LA-NSCLC) patients compared to conventional VMAT. The findings suggest IMPT significantly lowers HT3+ risk, particularly for patients with tumors close to the thoracic vertebral bodies (TVB), offering a promising avenue for personalized treatment selection.

What Problem Does This Paper Address?

Lung cancer, particularly LA-NSCLC, often requires concurrent chemoradiotherapy (CCRT). A significant challenge with this treatment is the high incidence of acute hematologic toxicity (HT3+), which can lead to treatment disruption and poorer outcomes. This toxicity is linked to radiation exposure of bone marrow, primarily located in the thoracic vertebral bodies (TVB). While proton therapy is known for its dosimetric advantages in sparing organs at risk, its specific benefit in reducing HT3+ in LA-NSCLC, especially with advanced techniques like IMPT, and identifying which patients benefit most, remains an area needing further exploration. This paper aims to quantify this benefit and identify patient subgroups that stand to gain the most from IMPT.

Methods

The researchers conducted a retrospective study on 20 LA-NSCLC patients. They generated both Volumetric Modulated Arc Photon Therapy (VMAT) and Intensity-Modulated Proton Therapy (IMPT) treatment plans for each patient, delivering a standard dose of 60 Gy in 30 fractions. Key organs at risk (OARs), including thoracic vertebral bodies (TVB), lungs, heart, esophagus, and spinal cord, were contoured. The study then calculated the Normal Tissue Complication Probability (NTCP) for grade ≥ 3 acute hematologic toxicity (HT3+) for both VMAT and IMPT plans using the Lyman-Kutcher-Burman (LKB) model. Patients were categorized as "significantly benefiting" from IMPT if their NTCP for HT3+ decreased by 10% or more (△NTCP_HT3+ ≥ 10%). Statistical analyses, including univariate analysis and Chi-square tests, were used to identify factors associated with this benefit, particularly the distance between the tumor and the TVB.

Datasets

The study utilized data from 20 retrospective LA-NSCLC patient cases. These cases were selected to represent a variety of tumor sizes, locations, and metastatic lymph node stations, providing diverse patient geometries. The data included GTV (Gross Tumor Volume), staging, primary tumor location, IASLC lymph node stations, and the closest distance to TVB. No new benchmark datasets were introduced; the study relied on existing patient data for its analysis.

Key Insights and Ideas

  • IMPT's Superiority in Bone Marrow Sparing: The study strongly suggests that IMPT, compared to VMAT, significantly reduces radiation dose to the thoracic vertebral bodies (TVB), a key source of bone marrow exposure. This dosimetric advantage is the hypothesized mechanism for reducing hematologic toxicity.
  • Distance is Destiny for HT3+ Reduction: The most striking finding is the critical role of tumor proximity to TVB. Patients with tumors closer than 0.7 cm to the TVB showed a significantly greater reduction in HT3+ risk with IMPT. This highlights a specific patient subgroup that can maximally benefit from proton therapy.
  • Model-Based Patient Selection: The study proposes a model-based approach to identify patients who would benefit most from IMPT for HT3+ reduction. This moves beyond a general application of proton therapy towards a more personalized and evidence-driven selection process.
  • Beyond TVB: Broader OAR Sparing: While the focus is on TVB and HT3+, IMPT also demonstrated dosimetric advantages for other OARs like lungs, heart, and esophagus, reinforcing its overall benefit in reducing radiation-induced toxicity.

Key Results

  • IMPT significantly reduced the dose to TVB, lungs, heart, esophagus, and spinal cord compared to VMAT.
  • The average NTCP for HT3+ was lower with IMPT (36.69 ± 6.07%) compared to VMAT (47.86 ± 8.88%), representing an average reduction of 11%.
  • Thirteen out of twenty patients (65%) experienced a reduction in NTCP for HT3+ of 10% or more with IMPT.
  • Patients with a tumor distance to TVB of ≤ 0.7 cm were significantly more likely to achieve a ≥ 10% reduction in NTCP for HT3+ (OR 2.75, 95% CI 1.26-6.02).
  • The subgroup with tumor distance ≤ 0.7 cm showed significantly higher absolute reductions in TVB dose parameters (V30, V40, and Dmean) compared to the > 0.7 cm subgroup.

Limitations and Future Work

  • Model Limitations: The NTCP model used was originally developed for photon therapy. While applied here, its direct applicability to proton therapy, which has different physical and biological properties, may have limitations.
  • Small Sample Size: The study included only 20 patients, which is a relatively small cohort. Larger, prospective studies are needed to validate these findings.
  • Lack of Clinical Outcome Data: This study focused on dosimetric and NTCP predictions. Future work should include clinical data to confirm if these dosimetric improvements translate into actual reductions in HT3+ and improved patient outcomes.
  • Future Directions: The authors suggest exploring advanced IMPT techniques like Spot-scanning Proton Arc therapy (SPArc) for further dose conformity and interplay effect mitigation. They also highlight the importance of understanding the role of bone marrow and lymphoid organ irradiation in immunosuppression and the potential for lymphopenia prediction. Further research into variable RBE models for proton therapy is also recommended.

Summary updated

Abstract

IMPT decreased the probability of HT3+ compared to VMAT by reducing the dose to the TVB in LA-NSCLC patients. Patients with tumor distance to TVB less than 0.7 cm are likely to benefit most from proton over photon therapy.
BibTeX
@inproceedings{xi2022redefine,
  author = {Cao Xi and Peilin Liu and Xianshu Gao and Shiyu Shang and Jiayu Liu and Zishen Wang and Mengmeng Su and Xuanfeng Ding},
  title = {{Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.812031},
}
Figure